**Core Concept**
Hypercalcemia is a condition characterized by elevated calcium levels in the blood. In the context of cancer, it often results from the production of parathyroid hormone-related protein (PTHrP) or other factors that stimulate osteoclast activity, leading to bone resorption and increased calcium release.

**Why the Correct Answer is Right**
Multiple myeloma is a type of plasma cell malignancy that frequently causes hypercalcemia due to the release of osteoclast-activating factors, such as PTHrP, interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha). These factors stimulate osteoclasts to resorb bone, leading to an increase in serum calcium levels. Additionally, myeloma cells can also produce factors that inhibit osteoblast function, further contributing to bone destruction.

**Why Each Wrong Option is Incorrect**
**Option A:** While lung cancer can cause hypercalcemia, it is less common compared to multiple myeloma. Lung cancer often leads to hypercalcemia through the production of PTHrP, but this is not as frequent as in multiple myeloma.
**Option B:** Breast cancer can cause hypercalcemia, especially in patients with bone metastases. However, this is less common than in multiple myeloma and typically occurs in the setting of advanced disease.
**Option C:** Renal cell carcinoma can cause hypercalcemia, often due to the production of PTHrP or other factors. However, this is relatively rare compared to multiple myeloma.

**Clinical Pearl / High-Yield Fact**
It's essential to remember that hypercalcemia in cancer patients often presents with non-specific symptoms, such as fatigue, weakness, and confusion. A high index of suspicion and thorough evaluation, including measurement of serum calcium and PTH levels, are crucial for diagnosing and managing hypercalcemia in these patients.

**Correct Answer:** C. Multiple myeloma.